Mahsa Tehrani, MD
Rheumatology · Vienna, VANPI 1710113378
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,738 of the $18,864 with a category attached, or 72.8%. 34 manufacturers reported payments, led by Novartis at 34.1% of the total. Reporting peaked in 2023 at $7,032 and has fallen 73.0% since, to $1,901 in 2025. Among rheumatology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 692 payments — averaging $27.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$6K
- Johnson & Johnson$2K
- AbbVie$2K
- Amgen$2K
- UCB, Inc.$2K
- Lilly USA, LLC$546
- plus $4K from 28 others
What the payments were for
- Consulting fees$3,80020%
- Travel & lodging$1,0245%
- Food & beverage$13,73873%
- Education$3022%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 72 | $6,440 |
| Johnson & Johnson(3 entities) | 113 | $2,172 |
| AbbVie | 96 | $2,128 |
| Amgen(2 entities) | 103 | $2,086 |
| UCB, Inc. | 98 | $1,596 |
| Lilly USA, LLC | 28 | $546 |
| GSK | 23 | $524 |
| Mallinckrodt Hospital Products Inc. | 14 | $437 |
| Pfizer | 19 | $399 |
| E.r. Squibb & Sons, L.L.C. | 21 | $372 |
| Bristol Myers Squibb | 22 | $271 |
| Aurinia Pharma U.S., Inc. | 12 | $263 |
| AstraZeneca(2 entities) | 9 | $236 |
| Genentech USA, Inc. | 11 | $210 |
| Janssen Scientific Affairs, LLC | 2 | $200 |
| Sandoz | 7 | $131 |
| Fresenius Kabi USA, LLC | 5 | $123 |
| ANI Pharmaceuticals, Inc. | 6 | $116 |
| Mallinckrodt Enterprises LLC | 3 | $89 |
| Radius Health, Inc. | 4 | $89 |
| Regeneron Healthcare Solutions, Inc. | 3 | $73 |
| Actelion Pharmaceuticals US, Inc. | 4 | $61 |
| Sobi, Inc | 2 | $48 |
| Hikma Pharmaceuticals USA | 3 | $42 |
| Sanofi | 2 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $29 |
| Organon | 1 | $23 |
| Boehringer Ingelheim | 1 | $21 |
| Bioventus LLC | 1 | $21 |
| Pacira Therapeutics, Inc. | 1 | $19 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Regeneron | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,864 in reported general payments places this provider in the 90th percentile of 159 rheumatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlarisCanakinumab/Pf | 11 | $483,112 |
| Humira(Cf) PenAdalimumab | 52 | $372,905 |
| Enbrel SureclickEtanercept | 29 | $262,555 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 19 | $109,045 |
| Cosentyx Unoready PenSecukinumab | 13 | $93,163 |
| Taltz AutoinjectorIxekizumab | 13 | $87,488 |
| Cimzia (2 Pack)Certolizumab Pegol | 15 | $82,376 |
| Xeljanz XrTofacitinib Citrate | 11 | $62,602 |
| ProliaDenosumab | 19 | $33,557 |
| RasuvoMethotrexate/Pf | 12 | $12,126 |
| Hydroxychloroquine Sulfate | 167 | $6,699 |
| MethotrexateMethotrexate Sodium | 88 | $2,145 |
| Cevimeline Hcl | 11 | $1,503 |
| Diclofenac Sodium | 42 | $924 |
| Celecoxib | 52 | $765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisIlaris | $6,440 | $483,11211 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,596 | $82,37615 claims |
| AmgenProlia | $2,086 | $33,55719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 159 rheumatology providers in Virginia.
Other rheumatology in Vienna
- Mahnaz MomeniVienna$15K
- Peter LipskyCharlottesville$1.3M
- Kristi MizelleNewport News$1.1M
- Phillip KempfArlington$321K
- Sharukh ShroffDanville$216K
- Michael StrachanRichmond$158K
- Karim MasriRichmond$147K
- Michael CannonVirginia Beach$145K
- Phong NguyenReston$127K
- Chase CorreiaHampton$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.